Literature DB >> 26119775

Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting.

E Reigadas1, L Alcalá1, M Marín1, A Martín1, C Iglesias1, E Bouza1.   

Abstract

Binary toxin (BT) has been associated with strains causing more severe Clostridium difficile infection (CDI), such as ribotype 027. Data on the outcome of patients having BT present in ribotypes other than 027 are scarce. Our objective was to investigate the association between BT isolates and outcome of CDI in a non-027 ribotype setting. We prospectively included CDI episodes (January-June 2013 and March-June 2014) from symptomatic patients aged >2 years. Epidemiological and clinical data were recorded. BT genes were detected using multiplex PCR. During the study period, we identified 326 episodes of CDI, of which 319 were available for molecular analysis. Of these, 54 (16·9%) were caused by C. difficile strains with BT. Most (90·7%) isolates with BT were ribotype 078/126. CDI patients with BT-positive strains did not differ from those with BT-negative strains in terms of recurrence (13·0% vs. 15·5%, P = 0·835), treatment failure (0·0% vs. 2·3%, P = 0·594), overall mortality (11·1% vs. 9·1%, P = 0·612), or CDI-related mortality (0·0% vs. 1·9%, P = 0·612). Multivariate regression revealed no association between BT and poor outcome. In conclusion, in a non-027 setting, we found that most BT isolates were 078/126 and were not associated with poor outcome.

Entities:  

Keywords:  Binary toxin; Clostridium difficile infection; outcome; recurrence; ribotype; severe

Mesh:

Substances:

Year:  2015        PMID: 26119775     DOI: 10.1017/S095026881500148X

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  11 in total

1.  Binary toxin and its clinical importance in Clostridium difficile infection, Belgium.

Authors:  T Pilate; J Verhaegen; M Van Ranst; V Saegeman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-08       Impact factor: 3.267

2.  Is there a relationship between the presence of the binary toxin genes in Clostridium difficile strains and the severity of C. difficile infection (CDI)?

Authors:  C E Berry; K A Davies; D W Owens; M H Wilcox
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-05       Impact factor: 3.267

3.  Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.

Authors:  Marie Pichenot; Rozenn Héquette-Ruz; Remi Le Guern; Bruno Grandbastien; Clément Charlet; Frédéric Wallet; Sophie Schiettecatte; Fanny Loeuillet; Benoit Guery; Tatiana Galperine
Journal:  Infection       Date:  2017-01-24       Impact factor: 3.553

4.  Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting - CORRIGENDUM.

Authors:  E Reigadas; L Alcalá; M Marín; A Martín; C Iglesias; E Bouza
Journal:  Epidemiol Infect       Date:  2016-06-17       Impact factor: 4.434

5.  The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients.

Authors:  Marcela Krutova; Vaclav Capek; Elka Nycova; Sabina Vojackova; Magda Balejova; Lenka Geigerova; Renata Tejkalova; Lenka Havlinova; Iva Vagnerova; Pavel Cermak; Lenka Ryskova; Petr Jezek; Dana Zamazalova; Denisa Vesela; Alice Kucharova; Dana Nemcova; Martina Curdova; Otakar Nyc; Pavel Drevinek
Journal:  Antimicrob Resist Infect Control       Date:  2020-06-30       Impact factor: 4.887

6.  The predictive value of quantitative nucleic acid amplification detection of Clostridium difficile toxin gene for faecal sample toxin status and patient outcome.

Authors:  Kerrie A Davies; Tim Planche; Mark H Wilcox
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

7.  Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge.

Authors:  Kaitlin Winter; Li Xing; Audrey Kassardjian; Brian J Ward
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

8.  Primary care clinics can be a source of exposure to virulent Clostridium (now Clostridioides) difficile: An environmental screening study of hospitals and clinics in Dallas-Fort Worth region.

Authors:  Jerry W Simecka; Kimberly G Fulda; Mark Pulse; Joon-Hak Lee; John Vitucci; Phung Nguyen; Patricia Taylor; Frank Filipetto; Anna M Espinoza; Sushma Sharma
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

9.  Epidemic ribotypes of Clostridium (now Clostridioides) difficile are likely to be more virulent than non-epidemic ribotypes in animal models.

Authors:  John C Vitucci; Mark Pulse; Leslie Tabor-Simecka; Jerry Simecka
Journal:  BMC Microbiol       Date:  2020-02-05       Impact factor: 3.605

10.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.